TransThera Sciences-B (02617.HK): Successfully Completes H-Share Placement, Raising Approximately HK$190 Million to Fund Core Product R&D
Newtimespace News: TransThera Sciences (Nanjing), Inc. (02617.HK) released an announcement on January 21, 2026, stating that the placement of its H-shares had been successfully completed.
According to the announcement, the company has successfully placed an aggregate of 2.1 million new H-shares at a placement price of HK$92.85 per share to no fewer than six placees, all of whom are independent professional, institutional or other investors. The number of placed shares accounts for approximately 0.69% of the total issued H-shares and 0.53% of the total share capital of the company upon completion of the placement.
The gross proceeds from the placement amount to approximately HK$194.99 million. After deducting relevant commissions and expenses, the net proceeds from the placement are approximately HK$190.14 million (equivalent to a net issue price of approximately HK$90.54 per share).
The company intends to apply the net proceeds from the placement as follows: approximately 60% (around HK$114.08 million) will be used to fund the ongoing clinical trials of its core product Tinengotinib as a monotherapy for cholangiocarcinoma (CCA) in China, as well as the R&D of the core product for other indications; approximately 30% (around HK$57.04 million) will be allocated to the R&D of other products in the pipeline (including TT-00973, TT-01488 and other molecules); approximately 10% (around HK$19.01 million) will be used for working capital replenishment and general corporate purposes.
This placement was conducted pursuant to the existing general mandate announced by the company on January 14, 2026. The board of directors believes that the placement will strengthen the company’s capital base and provide financial support for the continuous development of key drug pipelines, which is in the overall interests of the company and its shareholders.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
